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Abstract 
Objective 
To investigate perturbations in downstream signalling pathway activation and 
potential resistance mechanisms to EGFR and/or HER2 inhibition in cell line models 
of bladder cancer. 
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Methods 
We undertook a structured screening approach by phosphokinase array, followed by 
validation steps, to detect activated downstream signalling pathway nodes after 
therapeutic inhibition of EGFR and/or HER2 in bladder cancer cell lines. 
Results 
Erlotinib treatment of RT112 cells induced phosphorylation of 9 activated phospho-
protein targets (p38 MAPK (Thr180/Tyr182), GSK-3α/β (Ser21/9), MEK1/2 
(Ser218/222, Ser222/226), Akt (Ser473), TOR (Ser2448), Src (Tyr419), p27 (Thr198), 
p27 (Thr157) and PLCγ-1 (Tyr783)) whereas STAT4 (Tyr693) phosphorylation was 
reduced. Of these, p38 MAPK phosphorylation was confirmed to occur in response 
to inhibition of either EGFR and/or HER2 signalling through multiple validation steps 
including differing bladder cancer cell lines (RT112, UM-UC-3 and T24) and methods 
of receptor pathway inhibition (erlotinib, lapatinib, siRNA depletion of EGFR or 
HER2). Chemical inhibition of p38 MAPK with SB203580 led to inhibition of 
proliferation in RT112, UM-UC-3 and T24 cell lines (IC50 20.85 µM, 76.78 µM and 
79.12 µM respectively). Fractional effect analyses indicated a synergistic interaction 
for inhibition of cell proliferation when combining SB203580 with lapatinib.  
Conclusion 
p38 MAPK is a potential therapeutic target in bladder cancer and this strategy 
warrants further development in this disease. It may also allow for combination 
therapy strategies to be developed in conjunction with EGFR and/or HER2 inhibition. 
 
 
 
Introduction 
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Transitional cell carcinoma (TCC) of the bladder accounts for 10,000 new diagnoses 
and 5,000 deaths annually in the UK. Cisplatin based combination chemotherapy, in 
those fit enough to receive it, is the standard of care for initial systemic therapy. This 
results in a median survival of approximately 14 months as palliative treatment for 
metastatic TCC or an absolute survival advantage of 5-6% in the neoadjuvant setting 
prior to radical cystectomy or radiotherapy.1  Immunotherapy has recently been 
demonstrated to be effective as a second line palliative treatment but the disease is 
rapidly lethal in these circumstances with a median survival of only 10 months.2 
Furthermore, no molecularly targeted or stratified treatment strategy has yet been 
established for this disease. A significant unmet need therefore exists to develop 
new therapeutic approaches based on underlying disease biology.1 
 
The human epidermal growth factor receptor (HER) family are cell surface tyrosine 
kinase receptors which include the epidermal growth factor receptor (EGFR), HER2, 
HER3 and HER4. Cognate ligand binding induces homo- or hetero-dimerisation 
between HER family members followed by diverse downstream signalling pathway 
activation. Although their oncogenic activity is believed to be mediated primarily 
through the RAS/mitogen activated protein kinase (MAPK) and phosphatidylinositol 
3-kinase (PI3K)/AKT pathways, other pathways may also be involved including the 
signal transducer and activator of transcription (STAT) and phospholipase C and 
SRC/FAK pathways. Aberrant HER family activation in various cancers induces 
cellular proliferation, migration, attenuation of apoptosis, invasion and metastasis. 
EGFR and/or HER2 are established as clinical therapeutic targets for breast cancer, 
gastric cancer, non-small cell lung cancer, head and neck cancer and colorectal 
cancer.1, 3 
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EGFR and HER2 protein over-expression in TCC/bladder cancer is poorly defined at 
between 35-96% and 8-98% respectively.4-9 Increased expression of either has been 
linked to TCC grade, stage and survival outcomes.4-6, 8-11 Prognostic impact of EGFR 
and HER2 expression may link to their co-expression status with respect to each 
other and also with HER3 and HER4.7, 11 EGFR and/or HER2 inhibition have been 
demonstrated to be active in pre-clinical models and have been tested in early phase 
TCC clinical trials, either as single agents, or in combination with cytotoxic 
chemotherapy.1, 3, 12-15 Single agent clinical activity in response to targeted inhibition 
of either EGFR or HER2 is established but randomised data and clear demonstration 
of efficacy that would warrant routine use is awaited. Furthermore the requirement 
for a patient selection strategy and how this should be undertaken are currently 
unknown. 
 
Understanding of factors linked to response to EGFR and/or HER2 inhibition in TCC 
will likely be critical to patient selection for these approaches and may elucidate 
strategies for future clinical evaluation. We hypothesised that interrogation of 
downstream signalling pathway activation following chemical inhibition of EGFR 
and/or HER2 would allow for identification of critical molecular ‘nodes’ relevant for 
therapeutic efficacy. We demonstrate that p38 mitogen-activated protein kinase 
(MAPK) is activated in response to EGFR/HER2 inhibition in pre-clinical models for 
TCC/bladder cancer and that it represents a potential new therapeutic target.  
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Methods 
Reagents and cell lines 
Antibodies used were goat anti-EGFR, rabbit anti-HER4 (Santa Cruz Biotechnology, 
Texas, US); mouse anti-HER3 (Thermo Scientific, Basingstoke, UK); rabbit anti-actin 
(Sigma, Gillingham, UK); rabbit anti-HER2, rabbit anti-phospho Akt (Ser473), rabbit 
anti-Akt, rabbit anti-phospho ERK1/2 (Thr202/Tyr204), mouse anti-ERK1/2, rabbit 
anti-phospho p38 MAPK (Thr180/Tyr182) and rabbit anti-p38 MAPK (New England 
BioLabs, Hitchin, UK). Horseradish peroxidase (HRP)-conjugated secondary 
antibody was from GE Healthcare (UK). Erlotinib, lapatinib and SB203580 
(Selleckchem, Munich) were dissolved in dimethyl sulfoxide (DMSO) and stored as 
stock solutions at -20°C. Cell lines (HT1376, T24, RT112, RT112CP, UM-UC-3 and 
UM-UC-6) were maintained in Dulbecco’s modified Eagle medium or in Roswell Park 
Memorial Institute 1640 media (RPMI) supplemented with 10% (v/v) fetal bovine 
serum, 2mM L-glutamine, 100μg/ml penicillin G and 100μg/ml streptomycin (PAA 
Laboratories GmbH, Austria). All cell lines were obtained from the European 
Collection of Cell Cultures. RT112CP were a kind gift from Prof John Masters at 
University College London.16 
 
Immunoblotting 
Immunoblotting was performed as previously described.17 Representative examples 
of a minimum of 3 separate experiments are shown. 
 
Cell proliferation assays and assessment of synergistic interactions for 
combination chemical inhibition 
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Cell proliferation was measured as previously described using CellTiter 96 AQueous 
One Solution Reagent (Promega, Southampton, UK) or by using the CellTiter-Glo® 
2.0 assay (Promega, Southampton, UK) according to the manufacturer’s 
instructions.18 IC50 values calculated for SB203580 in RT112, UM-UC-3 and T24 
cells using GraphPad Prism software. Synergism for inhibition of cell proliferation as 
a result of combination drug exposure was assessed using fractional effect analyses 
using CalcuSyn software (version 2.0, Biosoft, Cambridge, UK) according to the 
manufacturer’s instructions and as previously described.18 
 
siRNA forward transfection 
RNA interference was performed with ON-TARGETplus siRNA SMARTpools against 
EGFR or HER2 and non-targeting controls (GE Healthcare, UK) transfected with 
INTERFERin transfection reagent (Polyplus Transfection Inc, New York, USA) 
according to the manufacturer’s instructions. Briefly, 1.5 – 3x105 cells per well were 
incubated overnight. The following day, 500 μl of Opti-MEM reduced serum medium 
(Invitrogen, UK) was mixed with 5 μl INTERFERin and 1.5 μl siRNA for 15 minutes at 
room temperature and the siRNA/INTERFERin complex was added to the cells for a 
final siRNA concentration of 50 nM.  
 
Human phosphokinase array 
A human phospho-kinase membrane-based sandwich immunoassay (Proteome 
Profiler Human Phospho-Kinase Array Kit ARY003, R&D Systems, Abingdon, UK) 
was used to detect simultaneously the relative phosphorylation levels of 46 protein 
kinase phosphorylation sites of potentially relevant signalling pathways downstream 
of EGFR and/orHER2. 3x106 cells were cultured overnight before treating for one 
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hour with the relevant drug or DMSO solvent control. Following EGFR and/or HER2 
inhibition the array was processed according to the manufacturer’s protocol. 
Phosphorylated protein was detected using ECL reagent on a ChemiDoc-It Imaging 
System (Ultra-Violet Products, UK) using VisionWorksLS Image Acquisition and 
Analysis software (UVP Ltd).  
 
Phosphokinase array data analysis 
Signals from the phosphokinase array were quantified using Quantity One software. 
Data were then analysed by each of three different methods: i) as raw data (pixel 
density), ii) as a percentage of the array positive control mean signal, and iii) as a 
percentage of the global mean of all signals on the array. Only phosphokinase 
changes that reached statistical significance (p<0.05) by each of these three analysis 
approaches were taken forward for subsequent investigation and validation. 
Statistical analysis was performed using Student’s t-test and presented for p values 
<0.01 and <0.05. 
  
Page 7 of 23
   
11 
 
Results 
Erlotinib and lapatinib response in bladder cancer cell lines 
Mechanisms for resistance to inhibition of EGFR and/or HER2 might include 
alterations to downstream signalling pathway activation. To investigate this 
hypothesis in bladder cancer cell lines we undertook an initial screen to assess 
activation, in terms of kinase phosphorylation status, through a phosphokinase array. 
We utilised prospectively determined criteria for subsequent selection and validation 
of altered downstream signalling pathway nodes (Additional file 1: Figure S1). Our 
approach was to incorporate both the EGFR inhibitor erlotinib and the dual 
EGFR/HER2 inhibitor lapatinib with the intention to detect downstream signalling 
impacts that were common to both drugs. RT112 cells were chosen for initial 
analyses, as they expressed relatively high levels of both EGFR and HER2 amongst 
a panel of bladder cancer cell lines assessed (Fig. 1A) and were sensitive to both 
erlotinib (IC50 6.6 µM) and lapatinib (IC50 6.1 µM) in cell proliferation experiments. In 
this cell line, downregulation of phospho-ERK1/2 was robust following exposure to 
the EGFR inhibitor erlotinib by 1 hour (Fig. 1B) and we therefore selected this time 
point for initial studies. 
 
1st phosphokinase array screen of erlotinib treatment of RT112 cells 
The phosphokinase array was used to interrogate RT112 cells after treatment with 
erlotinib for 1 hour at a dose of 5 times the IC50 value determined in cell proliferation 
experiments (data not shown). Increased expression was seen for 9 phospho-protein 
targets in erlotinib treated compared to control cells (Fig. 1C and Additional file 1: 
Figure S2 and S3), with consistent results achieved with each of the three data 
analysis methods used (Additional file 1: Figure S4A, B). These were p38 MAPK 
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(Thr180/Tyr182), GSK-3α/β (Ser21/9), MEK1/2 (Ser218/222, Ser222/226), Akt 
(Ser473), TOR (Ser2448), Src (Tyr419), p27 (Thr198), p27 (Thr157) and PLCγ-1 
(Tyr783). In addition STAT4 (Tyr693) phosphorylation was reduced. Discrepancy 
was seen with the phosphorylation status of p53 (Ser392) (upregulated when 
analysed by pixel density, but downregulated when analysed by the percentage of 
the positive control or percentage of the global mean of signals) and so it was 
excluded, based on our pre-determined analysis plan, from subsequent validation 
steps. 
 
Validation step 1 (2nd phosphokinase array) of lapatinib treatment of RT112 
cells 
We next undertook a validation step by retesting only the 10 phosphokinase targets 
confirmed to change on exposure to erlotinib by undertaking a second 
phosphokinase array experiment in RT112 cells but with the dual EGFR/HER2 
inhibitor lapatinib, again at 5 times its IC50 concentration for cell proliferation. In doing 
so, we validated 3 of the 10 phospho-proteins assessed that were again found to 
alter in their expression status. These were p38 MAPK (Thr180/Tyr182) and GSK-
3α/β (Ser21/9) which were upregulated and STAT4 (Tyr693) which was 
downregulated (Fig. 1D and Additional file 1: Figure S4c, 4d, S5 and S6). 
 
Validation step 2, individual phosphokinase experiments 
To further validate the two rounds of phosphokinase array results, we undertook 
Western blot analyses for phosphorylation status of p38 MAPK (Thr180/Tyr182), 
GSK-3α/β (Ser21/9) and STAT4 (Tyr693) in response to erlotinib or lapatinib 
exposure. We found consistent increases in phosphorylation of p38 MAPK in 
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response to either drug (Fig. 2A, B). However, no difference was confirmed in the 
phosphorylation status of GSK-3α/β or STAT4 (data not shown). The increase of p38 
MAPK phosphorylation in response to inhibition of EGFR or EGFR/HER2 was 
confirmed both in RT112 cells and also in T24 bladder cancer cells (Fig. 2A, B, C, 
D). 
 
We then extended the validation of our findings by replicating the impact on p38 
phosphorylation in response to either EGFR or HER2 depletion by siRNA in RT112 
cells (Fig. 2E). Depletion of either receptor increased p38 phosphorylation. 
 
Combination inhibition of p38 MAPK and EGFR +/- HER2 in bladder cancer cell 
lines 
We hypothesised that p38 MAPK phosphorylation in response to EGFR and/or 
HER2 inhibition could represent an escape mechanism to EGFR/HER2 directed 
therapy and represent a therapeutic target in bladder cancer cells. We first tested 
chemical inhibition of p38 MAPK with the pyridinyl imidazole compound SB203580 
and found an anti-proliferative effect in UM-UC-3, RT112 and T24 cell lines with 
mean IC50 values of 76.78 µM, 20.85 µM and 79.12 µM respectively (Fig 3).). Next 
we tested the effect, in UM-UC-3, T24 and RT112 cells, of dual EGFR/HER2 
inhibition using lapatinib in combination with p38 MAPK inhibition with SB203580. 
Cell growth inhibition when these drugs were combined was greater than the effect 
with either drug alone (Fig. 4A) in all cell lines tested and these differences were 
statistically significant (p<0.0001). Similar effects were seen when combining EGFR 
inhibition with erlotinib and SB203580 in all cell lines analysed (Fig. 4B)  
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Next we undertook fractional effect analyses to formally test for a synergistic 
interaction between lapatinib and SB203580 in RT112 cells (Fig. 4C). Of the dose 
combinations tested, if both drugs were each combined at 0.75 times their respective 
IC50 values or greater, then we achieved ~100% cell growth inhibition. The 
calculated combination index (CI) values, where values <1 indicate ‘synergy’, at IC50, 
IC75 and IC90 were 0.66, 0.59 and 0.53 respectively. Similar interactions with 
combination therapy were seen in T24 cells (Fig. 4D). The calculated CI values at 
ED50, ED75 and ED90 were 0.64, 0.53 and 0.45 respectively. 
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Discussion 
Chemotherapy remains the standard of care for the systemic therapy of muscle 
invasive bladder cancer but outcomes are modest. We have yet to see any 
molecularly targeted therapeutic strategies introduced for this disease and so a 
significant unmet clinical need remains.1 EGFR and HER2 are amongst the more 
promising therapeutic targets currently under clinical development in bladder cancer. 
However it remains unclear what the most appropriate selection strategy or the 
potential mechanisms of resistance to this approach might be. We took chemical 
inhibition of EGFR or EGFR/HER2, using agents currently in clinical evaluation for 
bladder cancer, as a starting point for a screen/validation approach to detect 
downstream signalling targets of potential therapeutic importance. Using this 
approach, we have identified p38 MAPK as a consistently activated downstream 
signalling node and were able to validate this across cell lines and with multiple 
approaches to EGFR and/or HER2 inhibition. 
 
p38 MAPK belongs to a family which also includes ERK1/2 (extracellular signal-
regulated kinases 1 and 2) and JNKs (c-Jun-N-terminal kinases).19  p38 MAPK exists 
as four isoforms (α, β, γ and δ) encoded by different genes. p38α is expressed at 
high levels in most cell types whereas p38β is expressed at lower levels and 
expression of the other two members, p38γ and p38δ, is tissue-specific.20 
Extracellular signals activate the MAPK cascade to phosphorylate p38α in threonine 
and tyrosine residues, resulting in a kinase activating conformational change.20 
Activated p38α phosphorylates multiple cellular targets, including DNA and RNA-
binding proteins involved in the regulation of gene expression, transcription factors 
(e.g., ATF2, MEF2A, SAP1, CHOP, Elk-1, STAT1, STAT4 and p53) serine and 
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threonine kinases (e.g., GSK-3β, MK2, MK3, MSK1 and MSK2) and regulatory 
proteins involved in cell cycle regulation (e.g., cyclin D1, cyclin D3 and p57kip2) 
apoptosis (e.g., Bax and BimEL) and cell survival (e.g., caspase-3 and caspase-8).20 
p38 MAPK impacts on diverse cellular functions including immune and inflammatory 
responses, the cell cycle, cellular proliferation, apoptosis and acts as a tumour 
suppressor.21-23 
 
The potential role of p38 MAPK in bladder cancer is poorly defined to date and has 
received little investigation. In a study of 91 primary bladder cancer samples p38 
MAPK expression was associated with higher tumour grade and detrusor muscle 
invasion 24.  In preclinical models, p38 MAPK was shown to regulate invasion of 
bladder cancer cells by modulating matrix metalloproteinases 2 and 9.25 Additionally, 
p38 MAPK activation may confer resistance to apoptosis and a survival advantage to 
bladder cancer cells.26 
 
Our screening approach to determine the impact of EGFR and/or HER2 chemical 
inhibition on downstream signalling detected consistent p38 MAPK phosphorylation 
in RT112 and T24 bladder cancer cells. We were then able to validate these findings 
by siRNA depletion of EGFR or HER2. This is in accordance with findings in 
glioblastoma multiforme cells after treating with the dual EGFR and HER2 inhibitor 
GW2974.27  Further investigation through combination treatment experiments 
including fractional effect assays showed that dual EGFR/HER2 inhibition with 
lapatinib combined with the p38 MAPK inhibitor SB203580 had a synergistic effect 
on cell proliferation inhibition in  UM-UC-3, RT112 and T24 cells. A possible 
explanation for synergism would be that lapatinib inhibits the activation of Ras-MAPK 
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and PI3K/Akt pathways, leading to cell cycle arrest and apoptosis, but at the same 
time, p38 MAPK may be activated as a survival mechanism to this inhibition which is 
susceptible to chemical inhibition. 
 
p38 MAPK is a pharmaceutical target for inhibition in non-malignant diseases such 
as asthma, rheumathoid arthritis, chronic obstructive pulmonary disease or 
inflammatory bowel disease.28 Earlier clinical experience with available agents 
suffered from target specificity limitations and off target toxicity however newer 
agents in clinical development may allow this to be addressed by improved target 
selectivity.29 Clinical evaluation of p38 MAPK inhibition in cancer might therefore be 
practical and has begun, for example in myelodysplastic syndromes.30 Our data 
provide a rationale now for clinical evaluation of both single agent p38 MAPK 
inhibition in bladder cancer and also potentially for its combination with EGFR/HER2 
inhibition. Initial studies are in development. Further pre-clincial development of this 
approach in urothelial cancer is also warranted including with in-vivo assessment 
with xenograft approaches. 
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Conclusion 
We have identified and validated p38 MAPK as a downstream signalling node that 
undergoes consistent phosphorylation in response to either EGFR or dual 
EGFR/HER2 inhibition using agents in current clinical evaluation in bladder cancer. 
Inhibition of p38 MAPK led to inhibition of cell proliferation in bladder cancer models 
and this effect synergised with dual EGFR/HER2 inhibition. This work detects p38 
MAPK as a potential therapeutic target in bladder cancer and that warrants further 
development. 
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Figure 1. (A) EGFR, HER2, HER3 and HER4 protein expression in a panel of 
bladder cancer cell lines. Cell lines were grown to near confluence and analysed by 
Western blot. β-actin was used as a sample loading control. (B) ERK1/2 
phosphorylation in response to erlotinib in RT112 bladder cancer cells. RT112 cells 
were treated with erlotinib at 5x the IC50 dose (33µM) for cell proliferation for the 
indicated time points followed by Western blot for phospho-ERK1/2 (Thr202/Tyr204) 
and total expression of ERK1/2. Representative of two separate experiments. Bar 
charts showing activation in phosphokinase array experiments in RT112 cells of 
those phospho-protein targets that reached pre-determined criteria for a statistically 
significant change after either (C) erlotinib or (D) lapatinib treatment compared to 
DMSO solvent control. The analysis shown here is undertaken by the ‘raw data’ 
(pixel density) approach. Error bars represent the standard deviation of duplicates. 
(UT, untreated; C, DMSO solvent control; Erl, erlotinib) 
 
Figure 2. Changes in phosphorylation of p38 MAPK in response to reduced 
signalling through EGFR and/or HER2 analysed by Western blot. (A and B) RT112 
cells were treated with erlotinib or lapatinib respectively for the indicated durations, 
or (C, D) T24 bladder cancer cells were treated with erlotinib or lapatinib for 2 hours, 
at doses of 2.5x and 5x the IC50 for cell proliferation. (E) EGFR or HER2 were 
depleted by siRNA knockdown in RT112 cells and analysed after incubation for 48 
hours. (p-p38, phosphorylated p38 MAPK (Thr180/Tyr182); p38, total p38 MAPK; 
UT, untreated; D, DMSO solvent control; C, control siRNA). β-actin was used as a 
sample loading control. 
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Figure 3. Proliferation of bladder cancer cells following treatment SB203580. Dose-
response curves in cell proliferation assays in RT112, UM-UC-3 and T24 bladder 
cancer cell lines treated with SB203580 for 3 days.  IC50 values calculated for 
SB203580 are indicated for each cell line. 
 
Figure 4. Proliferation of bladder cancer cells following treatment SB203580, 
lapatinib or erlotinib or in combination. (A) RT112, T24 and UM-UC-3 cells were 
treated with lapatinib, SB203580 or both in combination (each drug at its IC50 
concentration for each cell line respectively) or DMSO (solvent control) as indicated 
for 3 days. (B) RT112, T24 and UM-UC-3 cells were treated with erlotinib and 
SB203580 or both in combination (each drug at its IC50 concentration for each cell 
line respectively) or DMSO (solvent control) as indicated for 3 days.  (C and D) 
Combination index studies: (C) RT112 or (D) T24 cells were treated with lapatinib or 
SB203580, with each at the indicated multiples of the respective IC50 values for 
proliferation in each cell line or both in combination, or DMSO (solvent control). All 
results are expressed as the percentage metabolic activity in cell proliferation assays 
compared to DMSO treated cells. Each data point represents the mean of (A and B) 
3 or (C to D) 2 independent experiments determinations ± standard deviation. 
Statistical analysis in (A) and (B) was performed 2 way ANOVA (**** p<0.0001).  
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Supplementary Figure Legends 
 
Supplementary Figure 1. Schematic overview of the screening and validation 
pathway used to determine kinase phosphorylation patterns in bladder cancer cells 
following EGFR and/or HER2 signalling inhibition. 
 
Supplementary Figure 2. Image of the 1st human phosphokinase array experiment 
of erlotinib treated RT112 bladder cancer cells. RT112 cells were treated with 
erlotinib at 5x the IC50 dose (33µM) for cell proliferation for 1 hour. Proteins that had 
statistically significant changes in their phosphorylation status compared to DMSO 
solvent control exposed samples are indicated.  
 
Supplementary Figure 3. Data for the 1st human phosphokinase array experiment 
of erlotinib treated cells analysed according to three approaches as described in 
Methods (pixel density, % of positive control, % of global mean). Statistical analysis 
was performed using Student’s t-test. Statistically significant changes are highlighted 
in pink p<0.01 or yellow p<0.05. * Shows those targets for which statistically 
significant changes (p<0.05) were found by all three analysis methods.  
 
Supplementary Figure 4. Bar charts showing activation in phosphokinase array 
experiments in RT112 cells of those phospho-protein targets that reached pre-
determined criteria for a statistically significant change after either (a, b) erlotinib or 
(c, d) lapatinib treatment compared to DMSO solvent control. The analyses shown 
here were undertaken with respect to (a, c) the % of the positive control or (b, d) the 
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% of the global mean as indicated. Error bars represent the standard deviation of 
duplicates. 
 
Supplementary Figure 5. Image of the 2nd human phosphokinase array experiment 
of lapatinib treated RT112 bladder cancer cells. RT112 cells were treated with 
lapatinib at 5x the IC50 dose (30.5µM) for cell proliferation for 1 hour. Only the 10 
proteins that showed a consistent and statistically significant change in their 
phosphorylation status in the initial erlotinib screen (1st phosphokinase array 
experiment, Figure 2a, supplementary Figures 3 and 4) were considered (according 
to the pre-defined screen/validation plan, Supplementary Figure 1). Of these, 
proteins that had statistically significant changes in their phosphorylation status 
compared to DMSO solvent control exposed samples are indicated. 
 
Supplementary Figure 6. Data for the 2nd human phosphokinase array experiment 
of lapatinib treated cells analysed according to three approaches as described in 
Methods (pixel density, % of positive control, % of global mean). Only the 10 proteins 
that showed a consistent and statistically significant change in their phosphorylation 
status in the initial erlotinib screen (1st phosphokinase array experiment, Figure 2a, 
supplementary Figures 3 and 4) were considered (according to the pre-defined 
screen/validation plan, Supplementary Figure 1). Statistical analysis was performed 
using Student’s t-test. Statistically significant changes are highlighted in pink p<0.01 
or yellow p<0.05. * Shows those targets for which statistically significant changes 
(p<0.05) were found by all three analysis methods. 
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